Treatment with the fully human monoclonal ANGPTL3-blocking antibody evinacumab of individuals with mixed dyslipidemia with borderline high triglycerides prompted substantial, sustained reductions in triglycerides and VLDL-C levels in 2 randomized, double-blind, placebo-controlled, Phase 1 studies. Here, ANGPTL3 is linked to metabolic syndrome.